11,695 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by Oddo BHF Asset Management Sas

Oddo BHF Asset Management Sas purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 11,695 shares of the medical research company’s stock, valued at approximately $2,771,000.

Other institutional investors also recently made changes to their positions in the company. FMR LLC grew its position in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of IQVIA during the 3rd quarter worth about $147,683,000. 1832 Asset Management L.P. increased its position in IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after purchasing an additional 376,595 shares in the last quarter. Renaissance Technologies LLC acquired a new position in IQVIA during the second quarter valued at approximately $70,610,000. Finally, Impax Asset Management Group plc grew its stake in IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after buying an additional 264,555 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Down 0.7 %

Shares of NYSE IQV opened at $199.06 on Friday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a market capitalization of $36.13 billion, a P/E ratio of 26.12, a PEG ratio of 2.07 and a beta of 1.49. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The stock’s 50 day moving average price is $212.24 and its two-hundred day moving average price is $224.23.

Analyst Ratings Changes

Several equities analysts recently weighed in on IQV shares. Truist Financial reduced their target price on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday. Barclays decreased their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Evercore ISI dropped their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. TD Cowen decreased their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Robert W. Baird dropped their price objective on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $256.19.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.